Logo-ehsj
Epidemiol Health System J. 2023;10(3): 136-140.
doi: 10.34172/ehsj.2023.22

Scopus ID: 85175541460
  Abstract View: 793
  PDF Download: 190

Original Article

Trend in SARS-CoV-2 Antibodies Seroprevalence in Bukavu Between 2020 and 2023: A Hospital-Based Retrospective Study

Bertin Barhankabaga Bijira 1 ORCID logo, Justin Busingo Muderhwa 1 ORCID logo, Aimerance Barhinjibanwa Nabintu 1 ORCID logo, Yannick Cibinda Birato 1 ORCID logo, Delphin Katabana Murhula 1 ORCID logo, Philippe Bianga Katchunga 1,2* ORCID logo

1 Cliniques Universitaires de Bukavu, Faculty of Medicine, Université Officielle de Bukavu, Bukavu, DR Congo
2 Clinique Saint Luc de Bukavu, Bukavu, DR Congo
*Corresponding Author: Philippe Bianga Katchunga, Email: philkatch@yahoo.fr

Abstract

Background and aims: COVID-19 is undoubtedly underestimated in the South Kivu region due to the inaccessibility of reference diagnostic tests. In this context, serological tests could help estimate the disease’s circulation. This study analyzed the dynamics in the SARS-CoV-2 antibodies seroprevalence in Bukavu, East of the Democratic Republic of Congo.

Methods: The results of SARS-CoV-2 antibody tests performed in 2020 (n=1100), 2021 (n=508), and 2022-2023 (n=246) in 4 clinics in Bukavu underwent analysis. Any subject, regardless of age, gender, and origin, was eligible for voluntary SARS-CoV-2 antibody screening. The screening was performed to determine the immune status for professional reasons or clinical clarification in symptomatic subjects. For this purpose, 4 mL of blood was obtained from an antecubital venipuncture for biological analysis. The data were also collected anonymously and confidentially. These rapid lateral flow immunoassays (Cellex qSARS-CoV-2 immunoglobulin G/M [IgG/IgM], and QuickZen COVID-19 IgM/IgG) detected and differentiated SARS-CoV-2 antibodies in volunteer workers and patients.

Results: Between 2020 and 2023, the seroprevalence of SARS-CoV-2 antibodies (IgG+and IgM+) increased from 37.9% to 65.4% (P<0.0001). Early exposure to SARS-CoV-2 (IgM+/IgG-) increased significantly from 5.1% in 2020 to 11.4% in 2021, while it decreased significantly from 11.4% in 2021 to 4.5% in 2022-2023 (P<0.0001). Full immunization (IgM-/IgG+) increased from 2.5% in 2020 to 34.1% in 2022-2023. Age between 40 and 59 years (adjusted OR [95% CI]: 1.6 [1.3-2.1], P<0.0001) and≥60 years (adjusted OR [95% CI]: 1.6 [1.2-2.1], P=0.001), as well as exposure periods 2021 (adjusted OR [95% CI]: 2.0 [1.6-2.5], P<0.0001) and especially 2022-2023 (adjusted OR [95% CI]: 3.4 [2.5-4.7], P<0.0001) remained independent predictors of SARS-CoV-2 antibody seroprevalence.

Conclusion: The findings of the present study demonstrated extremely high exposure to SARS-CoV-2 and full immunization of a significant proportion of the screened subjects. These results would explain the marginalization of new waves of COVID-19 in Bukavu despite low access to vaccination.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 794

Your browser does not support the canvas element.


PDF Download: 190

Your browser does not support the canvas element.

Submitted: 19 Apr 2023
Revision: 22 Jul 2023
Accepted: 27 Aug 2023
ePublished: 29 Sep 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)